AR095984A1 - Factores artificiales de transcripción que regulan receptores nucleares y su uso terapéutico - Google Patents
Factores artificiales de transcripción que regulan receptores nucleares y su uso terapéuticoInfo
- Publication number
- AR095984A1 AR095984A1 ARP140101462A ARP140101462A AR095984A1 AR 095984 A1 AR095984 A1 AR 095984A1 AR P140101462 A ARP140101462 A AR P140101462A AR P140101462 A ARP140101462 A AR P140101462A AR 095984 A1 AR095984 A1 AR 095984A1
- Authority
- AR
- Argentina
- Prior art keywords
- receptor
- artificial transcription
- transcription factors
- useful
- treatment
- Prior art date
Links
- 102000040945 Transcription factor Human genes 0.000 title abstract 5
- 108091023040 Transcription factor Proteins 0.000 title abstract 5
- 108020005497 Nuclear hormone receptor Proteins 0.000 title abstract 3
- 108020004017 nuclear receptors Proteins 0.000 title abstract 3
- 102000006255 nuclear receptors Human genes 0.000 title 1
- 230000001105 regulatory effect Effects 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 102100032187 Androgen receptor Human genes 0.000 abstract 2
- 102100038595 Estrogen receptor Human genes 0.000 abstract 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 abstract 2
- 108090000079 Glucocorticoid Receptors Proteins 0.000 abstract 2
- 102100033417 Glucocorticoid receptor Human genes 0.000 abstract 2
- 208000019022 Mood disease Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 208000008589 Obesity Diseases 0.000 abstract 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 abstract 2
- 108010080146 androgen receptors Proteins 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 208000029078 coronary artery disease Diseases 0.000 abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract 2
- 235000020824 obesity Nutrition 0.000 abstract 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000015943 Coeliac disease Diseases 0.000 abstract 1
- 101000882584 Homo sapiens Estrogen receptor Proteins 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 101710185494 Zinc finger protein Proteins 0.000 abstract 1
- 102100023597 Zinc finger protein 816 Human genes 0.000 abstract 1
- 108091006088 activator proteins Proteins 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 abstract 1
- 108010038795 estrogen receptors Proteins 0.000 abstract 1
- 239000003862 glucocorticoid Substances 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 108091006086 inhibitor proteins Proteins 0.000 abstract 1
- 206010025135 lupus erythematosus Diseases 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 230000030648 nucleus localization Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 229940037128 systemic glucocorticoids Drugs 0.000 abstract 1
- 229960003604 testosterone Drugs 0.000 abstract 1
- 230000026683 transduction Effects 0.000 abstract 1
- 238000010361 transduction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
- C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Plant Pathology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Microbiology (AREA)
Abstract
La presente se relaciona con un factor de transcripción artificial que comprende una proteína con dedos de cinc polidáctil que apunta específicamente a la región promotora de un gen del receptor nuclear fusionado con un dominio de proteínas inhibidor o activador, una secuencia de localización nuclear y un dominio de transducción de proteínas. En ejemplos particulares, estas regiones promotoras de un gen del receptor nuclear regulan la expresión del receptor de glucocorticoides, el receptor de andrógenos o el receptor de estrógenos ESR1. Los factores artificiales de transcripción dirigidos contra el receptor de glucocorticoides son útiles en el tratamiento de enfermedades moduladas por glucocorticoides, tales como procesos inflamatorios, diabetes, obesidad, enfermedad de la arteria coronaria, asma, enfermedad celiaca y lupus eritematoso. Los factores artificiales de transcripción dirigidos contra el receptor de andrógenos son útiles en el tratamiento de enfermedades moduladas por testosterona, tal como varios tipos de cáncer, enfermedad de la arteria coronaria, trastornos metabólicos tales como obesidad o diabetes o trastornos del estado de ánimo tales como esquizofrenia, depresión o trastorno de hiperactividad con déficit de atención. Los factores artificiales de transcripción dirigidos contra el receptor de estrógenos son útiles en el tratamiento de enfermedades moduladas por estrógenos, tales como varios tipos de cáncer, enfermedad cardiovascular, osteoporosis o trastornos del estado de ánimo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13162198 | 2013-04-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR095984A1 true AR095984A1 (es) | 2015-11-25 |
Family
ID=48044673
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140101462A AR095984A1 (es) | 2013-04-03 | 2014-04-01 | Factores artificiales de transcripción que regulan receptores nucleares y su uso terapéutico |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20160046681A1 (es) |
| EP (1) | EP2981549A2 (es) |
| JP (1) | JP2016515597A (es) |
| AR (1) | AR095984A1 (es) |
| TW (1) | TW201514201A (es) |
| WO (1) | WO2014161884A2 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL274926B2 (en) | 2017-12-01 | 2026-04-01 | Encoded Therapeutics Inc | Pyrazolopyrimidines with activity against respiratory syncytial virus |
| US20220202957A1 (en) * | 2019-04-09 | 2022-06-30 | The Regents Of The University Of California | Long-lasting analgesia via targeted in vivo epigenetic repression |
| WO2020243651A1 (en) | 2019-05-29 | 2020-12-03 | Encoded Therapeutics, Inc. | Compositions and methods for selective gene regulation |
| WO2022241289A2 (en) * | 2021-05-14 | 2022-11-17 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Activity-inducible fusion proteins having a transcription factor and a heat shock protein 90 binding domain |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001083751A2 (en) * | 2000-04-28 | 2001-11-08 | Sangamo Biosciences, Inc. | Methods for binding an exogenous molecule to cellular chromatin |
| KR20070060115A (ko) * | 2004-09-16 | 2007-06-12 | 상가모 바이오사이언스 인코포레이티드 | 단백질 생산을 위한 조성물 및 방법 |
-
2014
- 2014-04-01 AR ARP140101462A patent/AR095984A1/es unknown
- 2014-04-01 TW TW103112112A patent/TW201514201A/zh unknown
- 2014-04-02 WO PCT/EP2014/056594 patent/WO2014161884A2/en not_active Ceased
- 2014-04-02 US US14/781,688 patent/US20160046681A1/en not_active Abandoned
- 2014-04-02 JP JP2016505807A patent/JP2016515597A/ja active Pending
- 2014-04-02 EP EP14714707.8A patent/EP2981549A2/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014161884A3 (en) | 2014-12-18 |
| US20160046681A1 (en) | 2016-02-18 |
| JP2016515597A (ja) | 2016-05-30 |
| EP2981549A2 (en) | 2016-02-10 |
| WO2014161884A2 (en) | 2014-10-09 |
| TW201514201A (zh) | 2015-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR095984A1 (es) | Factores artificiales de transcripción que regulan receptores nucleares y su uso terapéutico | |
| PH12015502114A1 (en) | 2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activities | |
| CO2017003396A2 (es) | Esteroides neuroactivos, composiciones y usos de los mismos | |
| TWD189837S (zh) | 定序儀之前面板 | |
| TWD170566S (zh) | 電鍋 | |
| CL2013002667A1 (es) | Compuestos derivados de ciclohexil-pirimidinona; composicion farmaceutica y su uso como moduladores de receptores de glucocorticoides para el tratamiento de hipertension, obesidad, diabetes, depresion psicotica mayor, vih, enfermedad de alzheimer, enfermedad de parkinson y estres. | |
| EA201790884A8 (ru) | 6-алкил-7-гидрокси-4-ен-3-оновые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr | |
| MX358390B (es) | Interleucina 6 y receptor de interleucina 6, humanizados. | |
| BR112012028764A2 (pt) | anticor-pos antifgfr2 | |
| EA201590747A1 (ru) | Способы лечения с использованием аденовируса | |
| TWD189616S (zh) | 電鍋 | |
| EA201790881A8 (ru) | 5-бета-6-алкил-7-гидрокси-3-оновые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr | |
| EP2875157A4 (en) | METHOD, KITS AND COMPOSITIONS FOR THE CLINICAL EVALUATION OF PROSTATE CANCER | |
| MX381239B (es) | Esteroides de 6.alfa.-alquil-6,7-diona como intermedios para la producción de moduladores esteroideos del receptor x farnesoide (fxr). | |
| MX375865B (es) | Esteroides de 6.alfa-alquil-3,7-diona como intermedios para la produccion de moduladores esteroideos del receptor x farnesoide (fxr). | |
| MX2015012274A (es) | Agentes de sub-regulacion del receptor de androgeno y uso de los mismos. | |
| MX358206B (es) | Animales no humanos que tienen un gen humanizado de un ligando inductor de la proliferacion. | |
| BR112017024945A2 (pt) | endurecedores de poliuretano bloqueados para adesivos de epóxi | |
| MX2015016031A (es) | Proceso para la preparacion de dehidroepiandrosterona y sus intermediarios. | |
| BR112015016059A2 (pt) | método e aparelho para determinação de mapa eletrônico | |
| WO2012154755A3 (en) | Creating and implementing language-dependent string pluralizations | |
| EP3619331A4 (en) | DIRECT CARBOTHERMAL REDUCTION OF CHROMITE USING A CATALYST FOR FERROCHROME ALLOY PRODUCTION | |
| BR112014008456A2 (pt) | regulação da expressão de receptor mediante distribuição de fatores de transcrição artificiais | |
| PL416092A1 (pl) | Klej do sztucznych rzęs na bazie cyjanoakrylanów | |
| CL2016001803A1 (es) | Compuestos derivados de heteroarilos bicíclicos fusionados, agonistas rxr; composición farmacéutica y su uso en el tratamiento del cáncer, diabetes, obesidad, dermatitis, psoriasis, alopecia, queratosis actínica, enfermedades cardiovasculares, metabólicas, hepáticas, cirrosis, enfermedades renales, fibrosis pulmonar, enfermedades oftálmicas, autoinmunes e inflamatorias, alzheimer, párkinson, esclerosis múltiple. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |